SecBot SecBot
425 ·Filed Jun 15, 2026

NNDM

Nano Dimension Ltd.
MIXED
Impact 7/10
Horizonweeks Processed5mo ago SEC0001104659-26-073777
Rule 425 M&A communications
Actionable Insight ◆ Mixed

Monitor the July 31, 2026 shareholder vote for signals of support; watch for definitive agreement execution and confirmatory due diligence results. The non-binding nature means deal could still fail, track any competing bids during the 30-day exclusivity period. If approved, the combined company's success hinges on Infinite's ability to commercialize its epigenetic diagnostics platform and achieve reimbursement.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.25
T+0 close · Jun 15, 2026 · via day close
Latest settled
+20.00%
T+60 · $1.50
Vs SPY
+19.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $1.25entry
  2. T+1 · 5mo ago −1.60%α −1.00% · $1.23
  3. T+5 · 5mo ago +11.20%α +12.58% · $1.39
  4. T+20 · 4mo ago +18.40%α +19.15% · $1.48
  5. T+60 · 2mo ago +20.00%α +19.00% · $1.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nano Dimension announced a non-binding term sheet to merge with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, in a stock-for-stock deal valuing Infinite at $890 million. Existing Nano shareholders would retain a meaningful minority stake in the combined company (to be renamed Infinite Epigenetics, ticker IEAI) based on a 20% premium to Nano's estimated net cash at closing, with the combined entity expected to have over $400 million in cash. The deal is transformative but non-binding, subject to definitive agreement, due diligence, shareholder votes, and regulatory approvals, with a key shareholder vote on July 31, 2026, to authorize continuation of the strategic process.

Key Financial Metrics

Deal Value
$890.0M
Deal Type
merger

Key Facts

  • Nano Dimension entered a non-binding term sheet to acquire Infinite Epigenetics in a stock-for-stock merger valuing Infinite at $890 million.
  • Existing Nano shareholders expected to retain meaningful minority ownership based on a 20% premium to Nano's estimated net cash at closing.
  • Combined company to operate as Infinite Epigenetics on Nasdaq under ticker IEAI, with over $400 million in cash at closing.
  • Infinite Epigenetics has collected 120,000+ epigenetic samples since 2020 and targets a $90B+ U.S. clinical diagnostics market.
  • Transaction subject to definitive agreement, confirmatory due diligence, Nano shareholder approval, regulatory approvals, and Nano re-domestication to the U.S.
  • Break fee of $10 million (2.5% of Nano Equity Valuation) payable by Nano in certain termination scenarios, with escrow required.
  • Shareholder vote on July 31, 2026, is a non-binding advisory vote to continue the strategic alternatives process, not a final vote on the transaction.

Financial Impact

Infinite Epigenetics valued at $890 million; combined company expected to have over $400 million cash at closing; Nano shareholders receive 20% premium to net cash plus contingent value rights for legacy asset proceeds.

dilutioncash_positionvaluation

Risk Factors

  • Non-binding term sheet, no guarantee of definitive agreement or closing.
  • Significant dilution for existing Nano shareholders who become minority owners.
  • Execution risk: Infinite Epigenetics is pre-revenue at scale and faces regulatory, reimbursement, and competitive hurdles.
  • Shareholder approval risk, the July 31 vote is advisory but signals sentiment.
  • Regulatory approvals required, including Israeli law and Nasdaq listing for combined entity.

Market Snapshot

Exchange
Nasdaq
Sector
Printed Circuit Boards
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001104659-26-073777
Document: tm2617934d1_ex99-2.htm0001104659-26-073777
Document: tm2617934d1_8k.htm0001104659-26-073777
Document: tm2617934d1_ex99-3.htm0001104659-26-073777
Document: tm2617934d1_ex99-1.htm0001104659-26-073777
Document: 0001104659-26-073777-index-headers.html0001104659-26-073777
Document: 0001104659-26-073777-index.html0001104659-26-073777
Document: 0001104659-26-073777.txt0001104659-26-073777

Track record

35 reports on NNDM

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +10.47% at T+20 after the Apr 6, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry $1.25 Now $1.19 −4.80% settles Nov 17
  2. Nov 12, 20264d ago 8-K Bearish 5/10 Entry $1.26 to $1.24 Now $1.19 +5.56% ▲ +1.59% +1.22% vs SPY
  3. Nov 10, 20266d ago DEF 14A Neutral 4/10 Entry $1.33 to $1.26 Now $1.19 −10.53% ▼ −5.26% −4.91% vs SPY
  4. Nov 10, 20266d ago Press Release Neutral 3/10 Entry $1.33 to $1.26 Now $1.19 −10.53% ▼ −5.26% −4.91% vs SPY
  5. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.32 to $1.34 Now $1.19 −9.85% ▲ +1.52% −0.85% vs SPY
  6. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  7. Nov 3, 202613d ago 144 Neutral 2/10 Entry $1.36 to $1.32 Now $1.19 −12.50% ▼ −2.94% −4.59% vs SPY
  8. Nov 2, 202614d ago 3 Neutral 3/10 Entry $1.36 to $1.32 Now $1.19 −12.50% ▼ −2.94% −4.59% vs SPY
  9. Oct 29, 202618d ago SC 13D/A Neutral 3/10 Entry $1.39 to $1.33 Now $1.19 −14.39% ▼ −4.32% −2.54% vs SPY
  10. Oct 26, 202621d ago 3 Neutral 3/10 Entry $1.43 to $1.42 Now $1.19 −16.78% ▼ −0.70% −1.04% vs SPY
Showing 10 of 35

US Market Status

Market Closed · Opens in 9h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026